Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
The finalists in each of the 32 categories for this year's MM&M Awards are revealed here.
The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.
The health insurer will offer Fit4D's diabetes coaching program to its members after testing the program during a pilot last year.
Dr. Stephen Ostroff took over as the FDA's acting commissioner when Dr. Margaret Hamburg stepped down in March.
Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company
Please open the PDF (named Index) below for a complete listing from our July 2015 issue
North American healthcare agencies and the holding companies that own them
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
Digital accounts for more than happiness
- Five things for pharma marketers to know: Tuesday, July 7
- Curious if you're a finalist in the MM&M Awards? Find out now
- Vertex's Orkambi nabs FDA approval but may face payer backlash
- Fit4D expands diabetes program with Healthfirst
- Steady Leadership, Focus on Infrastructure Expected from the FDA's "Acting" Head